Argeris Karabelas Net Worth

The estimated Net Worth of Argeris N Karabelas is at least $69.2 million dollars as of 3 September 2024. Argeris Karabelas owns over 10,000 units of Bausch Health Companies Inc stock worth over $132,186 and over the last 18 years he sold BHC stock worth over $68,648,019. In addition, he makes $387,500 as Independent Director at Bausch Health Companies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Argeris Karabelas BHC stock SEC Form 4 insiders trading

Argeris has made over 19 trades of the Bausch Health Companies Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of BHC stock worth $37,600 on 3 September 2024.

The largest trade he's ever made was selling 437,000 units of Bausch Health Companies Inc stock on 20 February 2007 worth over $11,812,110. On average, Argeris trades about 87,126 units every 155 days since 2006. As of 3 September 2024 he still owns at least 21,286 units of Bausch Health Companies Inc stock.

You can see the complete history of Argeris Karabelas stock trades at the bottom of the page.

Argeris Karabelas biography

Dr. Argeris (Jerry) N. Karabelas, Ph.D., is Independent Director of the Company. Since December 2001, Dr. Karabelas has been a Partner at Care Capital, LLC (“Care Capital”), a life sciences venture firm with $500M under management. Prior to his work at Care Capital, Dr. Karabelas was the founder and Chairman at Novartis BioVenture Fund, and served as Head of Healthcare and CEO of Worldwide Pharmaceuticals for Novartis Pharma AG. Prior to joining Novartis, Dr. Karabelas was Executive Vice President of SmithKline Beecham, where he was responsible for U.S. and European operations, regulatory and strategic marketing. Dr. Karabelas has been a director of REGENEXBIO Inc., a clinical-stage biotechnology company, since May 2015, and has served on the board of Braeburn Pharmaceuticals, Inc., a privately-held specialty pharmaceuticals company, since 2015. Dr. Karabelas previously served as Chairman of Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company (which merged with Rocket Pharmaceuticals, Inc. in 2017), from June 2012 to June 2016.

What is the salary of Argeris Karabelas?

As the Independent Director of Bausch Health Companies Inc, the total compensation of Argeris Karabelas at Bausch Health Companies Inc is $387,500. There are 13 executives at Bausch Health Companies Inc getting paid more, with Joseph Papa having the highest compensation of $17,141,600.

How old is Argeris Karabelas?

Argeris Karabelas is 67, he's been the Independent Director of Bausch Health Companies Inc since 2016. There are 4 older and 18 younger executives at Bausch Health Companies Inc. The oldest executive at Bausch Health Companies Inc is Richard De Schutter, 79, who is the Independent Director.

What's Argeris Karabelas's mailing address?

Argeris's mailing address filed with the SEC is C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.

Insiders trading at Bausch Health Companies Inc

Over the last 6 years, insiders at Bausch Health Companies Inc have traded over $2,786,244 worth of Bausch Health Companies Inc stock and bought 6,317,686 units worth $110,094,785 . The most active insiders traders include John Paulson, Argeris N Karabelas et Brett Icahn. On average, Bausch Health Companies Inc executives and independent directors trade stock every 36 days with the average trade being worth of $824,564. The most recent stock trade was executed by Seana Carson on 5 September 2024, trading 13,370 units of BHC stock currently worth $83,028.

What does Bausch Health Companies Inc do?

bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###

Complete history of Argeris Karabelas stock trades at Regenxbio Inc, Vanda Pharmaceuticals Inc et Bausch Health Companies Inc

Bausch Health Companies Inc executives and stock owners

Bausch Health Companies Inc executives and other stock owners filed with the SEC include:

• Joseph Papa,
  Chairman of the Board, Chief Executive Officer
• Paul Herendeen,
  Chief Financial Officer, Executive Vice President
• Joseph C. Papa,
  CEO & Chairman
• Thomas Appio,
  President & Co-Head Bausch + Lomb/International
• William Humphries,
  
• Christina Ackermann,
  Executive Vice President, General Counsel
• Thomas J. Appio,
  Pres & Co-Head Bausch + Lomb/International
• Paul S. Herendeen,
  Exec. VP and Advisor to Chairman & CEO
• Joseph Gordon,
  President & Co-Head Bausch + Lomb/International
• Christina M. Ackermann,
  Exec. VP, Gen. Counsel & Head of Commercial Operations
• Thomas Ross,
  Lead Independent Director
• Russel Robertson,
  Independent Director
• Robert Power,
  Independent Director
• Argeris Karabelas,
  Independent Director
• Sarah Kavanagh,
  Independent Director
• D. Robert Hale,
  Independent Director
• Amy Wechsler,
  Independent Director
• Richard De Schutter,
  Independent Director
• Andrew Charles von Eschenbach,
  Independent Director
• John Paulson,
  Independent Director
• Tom G. Vadaketh,
  Chief Financial Officer
• Frederick J. Munsch,
  Controller & Chief Accounting Officer
• Kelly Webber,
  Sr. VP & Chief HR Officer
• Stacey Williams,
  VP of Marketing
• Michael McMyne,
  VP of Sales
• Arthur J. Shannon,
  Sr. VP and Head of Investor Relations & Communications
• Dr. Robert F. Butz,
  VP of Medical & Scientific Affairs
• Osama A. Eldessouky,
  CFO & Exec. VP
• Christian A Garcia,
  Director
• Frank D. Lee,
  Director
• Mark C. Mc Kenna,
  President, Salix
• Holdings, L.P.Value Act Hol...,
  
• Brett Icahn,
  Director
• Steven D Miller,
  Director
• Tom George Vadaketh,
  EVP, Chief Financial Officer
• Holdings, L.P.Value Act Cap...,
  
• Aimee J. Lenar,
  EVP, US Pharma
• Seana Carson,
  EVP, General Counsel
• David Robert Value Act Hold...,
  
• Sam Eldessouky,
  EVP & Chief Financial Officer
• Frederick Munsch,
  SVP, Controller and CAO
• Robert Spurr,
  President, U.S. Businesses
• Richard Mulligan,
  Director
• John S Barresi,
  SVP, Controller & CAO
• Jean Jacques Charhon,
  EVP, CFO